The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells

Helicobacter

Volumn 13, Issue 3, 2008, Pages 174-182

  Iwamoto, Jun Ichi ^a   Mizokami, Yuji ^a   Takahashi, Kimiko ^a   Matsuoka, Takeshi ^a   Matsuzaki, Yasushi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

COX 2 PGE2 pathway; Gastric cancer cells; Helicobacter pylori; uPA receptor (uPAR); Urokinase type plasminogen activator (uPA)

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; UROKINASE; UROKINASE RECEPTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER CELL; CANCER CELL CULTURE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INDUCTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; TUMOR VASCULARIZATION;

CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HELICOBACTER PYLORI; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR; XANTHONES;

HELICOBACTER PYLORI;

EID: 43449100392     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00597.x     Document Type: Article

References (38)

1. Jones PA, De Clerck YA. Extracellular matrix destruction by invasive tumor cells. Cancer Metastasis Rev 1982 1 : 289 317.
2. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993 4 : 197 250.
3. Matrisan LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990 6 : 121 5.
4. Dano K, Andreasen PA, Gronbahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Palsminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985 44 : 139 266.
5. Vassalli JD, Sappino A, Belin D. The plasmonigen a activator/plasmin system. J Clin Invest 1991 88 : 1067 72.
6. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996 49 : 117 37.
7. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator, proenzyme, receptor, and inhibitors. J Cell Biol 1987 104 : 801 4.
8. Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res 1995 313 : 54 63.
9. Reilly D, Andreasen PA, Duffy MJ. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Blood Coagul Fibrinolysis 1991 2 : 47 50.
10. Miseljic S, Galandiuk S, Myers SD, Wittliff JL. Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease. J Clin Lab Anal 1995 9 : 413 7.
11. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 1997 79 : 878 83.
12. Iwamoto J, Takahashi K, Mizokami Y, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokoube K, Matsuoka T. Expression of uroknase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin. Dig Dis Sci 2003 48 : 2247 56.
13. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981 41 : 4629 36.
14. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and, malignant breast tissues. Cancer 1996 77 : 1079 88.
15. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993 34 : 80 5.
16. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991 51 : 274 81.
17. Wilhelm O, Schmitt M, Hõhl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995 13 : 296 302.
18. Mori N, Sato H, Hayashibara T, Senba M, Geleziunas R, Wada A, Hirayama T, Yamamoto N. Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factorκB. Gasteroenterology 2003 124 : 983 92.
19. Crawford HC, Krishna US, Israel DA, Matrisian LM, Washington MK, Peek RM Jr. Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology 2003 125 : 1125 36.
20. Kitadai Y, Sasaki A, Ito M, Yanaka S, Oue N, Yasui W, Aihara M, Imagawa K, Haruma K, Chayama K. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric cancer cells. Bio Chem Res Comm 2003 311 : 809 14.
21. Kim MH, Yoo HS, Chang HJ, Hong MH, Kim HD, Chung IJ, Shin BA, Cho MJ, Ahn BW, Jung YD. Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1. Bio Chem Res Comm 2005 333 : 874 80.
22. Verro A, Noble PJM, Pritchard DM, Kennedy S, Hart CA, Dimaline R, Dockray GJ. Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-κB and RhoA: implications for invasion and apoptosis. Cancer Res 2004 64 : 1695 702.
23. Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Otubo T, Miura S, Narasaka T, Shimokobe K, Matsuoka T. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in the gastric cancer cells and effects of Helicobacter pylori. Scand J Gastroenterol 2005 40 : 783 93.
24. Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999 116 : 1319 29.
25. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999 94 : 1218 23.
26. Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P, Acquaviva AM, Del Vecchio Blanco C, Bruni CB, Zarrilli R. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998 273 : 28560 3.
27. 2 synthesis in rat gastric epithelial cells in vitro. J Gastroenterol Hepatol 2006 21 : 754 8.
28. Pai R, Nakamura T, Moon WS, Tarnawski AA. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003 17 : 1640 7.
29. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005 26 : 1393 9.
30. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002 19 : 527 34.
31. Evans DM, Sloan Stakleff KD. Control of pulmonary metastasis of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin Exp Metastasis 2004 21 : 339 46.
32. Takeuchi K, Araki H, Umeda M, Komoike Y, Suzuki K. Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: a study using rats and knockout mice. J Pharmacol Exp Ther 2001 297 : 1160 5.
33. Araki H, Ukawa H, Sugawa Y, Yagi K, Suzuki K, Takeuchi K. The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther 2000 14 : 116 24.
34. Pang L, Knox AJ. Bradykinin stimulates IL-8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products. J Immunol 1998 161 : 2509 15.
35. 2 receptor. J Biol Chem 1994 269 : 6163 9.
36. Shapiro RL, Duquette JG, Roses DF, et al. Induction of primary cutaneous malanocytic neoplasms in urokinase-type plasminogen activator-deficient and wildtype mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996 56 : 3597 604.
37. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is related in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cencer Res 2000 60 : 5839 47.
38. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001 10 : 393 416.